PGAM
HZNP

Princeton Global Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Princeton Global Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-500
Closed -$57.8K – 687
2023
Q3 		$57.8K Buy
+500
New +$53.7K 0.02% 234

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Princeton Global Asset Management's HZNP Position: Q4 2023 in Review

Princeton Global Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 500 shares — an estimated $57.8K sold.

Princeton Global Asset Management first reported a position in HZNP in Q3 2023 and held it in 1 quarter. The position peaked at $57.8K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Princeton Global Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Princeton Global Asset Management sold 500 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $57.8K.
  • Princeton Global Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2023 and held it in 1 quarter.
  • Princeton Global Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $57.8K in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Princeton Global Asset Management's 13F filing for Q4 2023, filed 22 Jan 2024.